Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
Enzo Biochem (NYSE:ENZ) filed its Q2 FY23 report, revealing revenues of $16.3 million, marking a 52% decrease from $34.0 million in Q2 FY22 due to reduced COVID testing. The Clinical Labs segment contributed $8.8 million, a 63% decline year-over-year, while Enzo Life Sciences generated $7.5 million, stabilizing near Q2 FY22 levels. Notably, January 2023 saw the firm's second-highest monthly revenue in over a decade. The company entered an asset purchase agreement for its Clinical Labs assets, aiming to unlock shareholder value and optimize its remaining assets. No financial call was held for this quarter.
- January 2023 revenue marked the second highest monthly revenue in over a decade.
- Q2 FY23 Enzo Life Sciences revenue stable compared to Q2 FY22, with 6% growth sequentially from Q1 FY23.
- Q2 FY23 overall revenue decreased 52% year-over-year due to decline in COVID testing.
- Clinical Labs segment revenue fell 63% compared to Q2 FY22, impacted by reduced COVID testing income and payer adjustments.
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division
- Enzo Life Sciences reports revenue of
FARMINGDALE, NY, March 21, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023 (Q2 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.
On March 16, 2023, Enzo Biochem announced that the Company entered into an Asset Purchase Agreement with respect to the sale of substantially all of the operating assets and assignment of certain liabilities which are necessary to operate the business of the Clinical Labs division. “This acquisition was part of an effort to evaluate strategic initiatives for Enzo Biochem that was initiated in 2022, in collaboration with the investment bank Jefferies LLC, said Hamid Erfanian, CEO of Enzo Biochem. By unlocking significant value for Enzo shareholders, the transaction positions Enzo to consider strategies to maximize the potential and value of the company’s remaining assets, including the Enzo Life Sciences segment.”
Second Quarter 2023 Revenue Results
- Revenues reached
$16.3M in the second quarter, a decrease of52% compared to$34.0M in the second quarter of last year and a decrease of11% sequentially compared to the first quarter of FY23. The decrease compared to Q2 FY22 was driven by the decline of COVID testing and timing of bulk product orders. - Q2 FY23 revenues for Enzo Life Sciences were
$7.5 million . After adjusting for a bulk order in the prior year, Q2 FY23 revenues were near flat compared to Q2 FY22. Revenues grew6% when compared to the sequential period of Q1 FY23, with Europe contributing approximately20% growth. The January 2023 revenue was the second highest monthly revenue in over 10 years. - Q2 FY23 revenues for the Clinical Lab segment were
$8.8 million , a decrease of63% compared to the$23.7 million in the second quarter of last year, primarily impacted by the decline in COVID testing revenues. Non-COVID testing accessions grew7% compared to the same period in the prior year, but those revenues declined due to payer and liquidation rate adjustments, as well as a charge to revenue due to a Medicaid audit.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. For more information, please visit Enzo.com or follow Enzo Biochem on Twitter and LinkedIn.
Forward-Looking Statements
Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2022. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
###
| Enzo Biochem Contacts | ||
| For Enzo Biochem: | For Media: | For Investors: |
| Patricia Eckert, Interim CFO 631-755-5500 peckert@enzo.com | Lynn Granito Berry & Company Public Relations 212-253-8881 lgranito@berrypr.com | Chris Calabrese LifeSci Advisors, LLC 917-680-5608 ccalabrese@lifesciadvisors.com |
FAQ
What were Enzo Biochem's second quarter results for FY23?
How did Enzo Life Sciences perform in Q2 FY23?
What led to the decline in Enzo Biochem's Clinical Labs revenue?
What strategic actions is Enzo Biochem taking for its Clinical Labs division?
